サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1178025

子癇前症診断の世界市場：検査タイプ別（血液検査、尿検査、その他）、製品・サービス別（装置、試薬・消耗品、サービス）－業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）

Preeclampsia Diagnostics Market (Test Type: Blood Test, Urine Test, and Others; Product & Services: Instruments, Reagents & Consumables, and Services) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 176 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
子癇前症診断の世界市場：検査タイプ別（血液検査、尿検査、その他）、製品・サービス別（装置、試薬・消耗品、サービス）－業界分析、市場規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年11月16日
発行: Transparency Market Research
ページ情報: 英文 176 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の子癇前症診断市場について調査分析し、市場概要、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の子癇前症診断市場

第4章 市場概要

  • イントロダクション
    • セグメントの定義
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の子癇前症診断市場の分析と予測（2017年～2031年）
    • 市場収益予測（100万米ドル）

第5章 主な洞察

  • 技術の進歩
  • 世界の主要国における疾患の有病率と発生率
  • 規制シナリオ：地域/世界別
  • 主要な業界イベント（合併、買収、パートナーシップ、コラボレーションなど）
  • COVID-19パンデミックが業界に与える影響

第6章 世界の子癇前症診断市場の分析と予測：検査タイプ別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場金額予測（2017年～2031年）：検査タイプ別
    • 血液検査
    • 尿検査
    • その他
  • 市場の魅力：検査タイプ別

第7章 世界の子癇前症診断市場の分析と予測：製品・サービス別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場金額予測（2017年～2031年）：製品・サービス別
    • 装置
    • 試薬・消耗品
    • サービス
  • 市場の魅力：製品・サービス別

第8章 世界の子癇前症診断市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場金額予測（2017年～2031年）：エンドユーザー別
    • 病院
    • 診断センター
    • その他
  • 市場の魅力：エンドユーザー別

第9章 世界の子癇前症診断市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：国/地域別

第10章 北米の子癇前症診断市場の分析と予測

第11章 欧州の子癇前症診断市場の分析と予測

第12章 アジア太平洋の子癇前症診断市場の分析と予測

第13章 ラテンアメリカの子癇前症診断市場の分析と予測

第14章 中東およびアフリカの子癇前症診断市場の分析と予測

第15章 競合情勢

  • 市場参入企業：競合マトリックス（層と企業規模別）
  • 企業プロファイル
    • Abbott Laboratories
    • Danaher Corporation（Beckman Coulter, Inc.）
    • Siemens Healthineers AG
    • Cardinal Health
    • F. Hoffmann-La Roche Ltd.
    • Bio-Rad Laboratories, Inc.
    • ARKRAY, Inc.
    • Sera Prognostics
    • Metabolomic Diagnostics Ltd.
    • Diabetomics, Inc.
    • ACON Laboratories, Inc.
    • DIRUI Industrial Co., Ltd.
図表

List of Tables

  • Table 01: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 02: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017-2031
  • Table 03: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 07: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017-2031
  • Table 08: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 09: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 11: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017-2031
  • Table 12: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 15: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017-2031
  • Table 16: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 19: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017-2031
  • Table 20: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 23: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by Product & Services, 2017-2031
  • Table 24: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Preeclampsia Diagnostics Market Value Share, by Test Type, 2021
  • Figure 03: Preeclampsia Diagnostics Market Value Share, By Product & Services, 2021
  • Figure 04: Preeclampsia Diagnostics Market Value Share, by End-user 2021
  • Figure 05: Global Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 06: Global Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 07: Global Preeclampsia Diagnostics Market Value (US$ Mn), by Blood Test, 2017-2031
  • Figure 08: Global Preeclampsia Diagnostics Market Value (US$ Mn), by Urine Test, 2017-2031
  • Figure 09: Global Preeclampsia Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 10: Global Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031
  • Figure 11: Global Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022-2031
  • Figure 12: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Instruments, 2017-2031
  • Figure 13: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Reagents & Consumables, 2017-2031
  • Figure 14: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Services, 2017-2031
  • Figure 15: Global Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 16: Global Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 17: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Hospitals, 2017-2031
  • Figure 18: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Diagnostic Centers, 2017-2031
  • Figure 19: Global Preeclampsia Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Preeclampsia Diagnostics Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 21: Global Preeclampsia Diagnostics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 22: North America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: North America Preeclampsia Diagnostics Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 24: North America Preeclampsia Diagnostics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 25: North America Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 26: North America Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 27: North America Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031
  • Figure 28: North America Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022-2031
  • Figure 29: North America Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 30: North America Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 31: Europe Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 32: Europe Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 33: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 34: Europe Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 35: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 36: Europe Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031
  • Figure 37: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022-2031
  • Figure 38: Europe Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 39: Europe Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 40: Asia Pacific Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 42: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 43: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 44: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 45: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031
  • Figure 46: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022-2031
  • Figure 47: Asia Pacific Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 48: Asia Pacific Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 49: Latin America Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Latin America Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 51: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 52: Latin America Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 53: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 54: Latin America Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031
  • Figure 55: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022-2031
  • Figure 56: Latin America Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 57: Latin America Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 58: Middle East & Africa Preeclampsia Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 59: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 60: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 61: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 62: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 63: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, By Product & Services, 2021 and 2031
  • Figure 64: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, By Product & Services, 2022-2031
  • Figure 65: Middle East & Africa Preeclampsia Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 66: Middle East & Africa Preeclampsia Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
目次
Product Code: TMRGL32423

TMR's report on the global preeclampsia diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global preeclampsia diagnostics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global preeclampsia diagnostics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the preeclampsia diagnostics market.

The report delves into the competitive landscape of the global preeclampsia diagnostics market. Key players operating in the global preeclampsia diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global preeclampsia diagnostics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Preeclampsia Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Preeclampsia Diagnostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Disease Prevalence & Incidence Rate globally with key countries
  • 5.3. Regulatory Scenario by Region/globally
  • 5.4. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
  • 5.5. COVID-19 Pandemic Impact on Industry

6. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Test Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Test Type, 2017-2031
    • 6.3.1. Blood Test
    • 6.3.2. Urine Test
    • 6.3.3. Others
  • 6.4. Market Attractiveness By Test Type

7. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Product & Services

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Product & Services, 2017-2031
    • 7.3.1. Instruments
    • 7.3.2. Reagents & Consumables
    • 7.3.3. Services
  • 7.4. Market Attractiveness By Product & Services

8. Global Preeclampsia Diagnostics Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others
  • 8.4. Market Attractiveness By End-user

9. Global Preeclampsia Diagnostics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America Preeclampsia Diagnostics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Test Type, 2017-2031
    • 10.2.1. Blood Test
    • 10.2.2. Urine Test
    • 10.2.3. Others
  • 10.3. Market Value Forecast, by Product & Services, 2017-2031
    • 10.3.1. Instruments
    • 10.3.2. Reagents & Consumables
    • 10.3.3. Services
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Diagnostic Centers
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Test Type
    • 10.6.2. By Product & Services
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Preeclampsia Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Test Type, 2017-2031
    • 11.2.1. Blood Test
    • 11.2.2. Urine Test
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Product & Services, 2017-2031
    • 11.3.1. Instruments
    • 11.3.2. Reagents & Consumables
    • 11.3.3. Services
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Diagnostic Centers
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-Region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Test Type
    • 11.6.2. By Product & Services
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-Region

12. Asia Pacific Preeclampsia Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Test Type, 2017-2031
    • 12.2.1. Blood Test
    • 12.2.2. Urine Test
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Product & Services, 2017-2031
    • 12.3.1. Instruments
    • 12.3.2. Reagents & Consumables
    • 12.3.3. Services
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Hospitals
    • 12.4.2. Diagnostic Centers
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-Region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Test Type
    • 12.6.2. By Product & Services
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-Region

13. Latin America Preeclampsia Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Test Type, 2017-2031
    • 13.2.1. Blood Test
    • 13.2.2. Urine Test
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Product & Services, 2017-2031
    • 13.3.1. Instruments
    • 13.3.2. Reagents & Consumables
    • 13.3.3. Services
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Hospitals
    • 13.4.2. Diagnostic Centers
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-Region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Test Type
    • 13.6.2. By Product & Services
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-Region

14. Middle East & Africa Preeclampsia Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Test Type, 2017-2031
    • 14.2.1. Blood Test
    • 14.2.2. Urine Test
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Product & Services, 2017-2031
    • 14.3.1. Instruments
    • 14.3.2. Reagents & Consumables
    • 14.3.3. Services
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Hospitals
    • 14.4.2. Diagnostic Centers
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-Region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Test Type
    • 14.6.2. By Product & Services
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-Region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Company Profiles
    • 15.2.1. Abbott Laboratories
      • 15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.1.2. Product Portfolio
      • 15.2.1.3. Financial Overview
      • 15.2.1.4. SWOT Analysis
      • 15.2.1.5. Strategic Overview
    • 15.2.2. Danaher Corporation (Beckman Coulter, Inc.)
      • 15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.2.2. Product Portfolio
      • 15.2.2.3. Financial Overview
      • 15.2.2.4. SWOT Analysis
      • 15.2.2.5. Strategic Overview
    • 15.2.3. Siemens Healthineers AG
      • 15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.3.2. Product Portfolio
      • 15.2.3.3. Financial Overview
      • 15.2.3.4. SWOT Analysis
      • 15.2.3.5. Strategic Overview
    • 15.2.4. Cardinal Health
      • 15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.4.2. Product Portfolio
      • 15.2.4.3. Financial Overview
      • 15.2.4.4. SWOT Analysis
      • 15.2.4.5. Strategic Overview
    • 15.2.5. F. Hoffmann-La Roche Ltd.
      • 15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.5.2. Product Portfolio
      • 15.2.5.3. Financial Overview
      • 15.2.5.4. SWOT Analysis
      • 15.2.5.5. Strategic Overview
    • 15.2.6. Bio-Rad Laboratories, Inc.
      • 15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.6.2. Product Portfolio
      • 15.2.6.3. Financial Overview
      • 15.2.6.4. SWOT Analysis
      • 15.2.6.5. Strategic Overview
    • 15.2.7. ARKRAY, Inc.
      • 15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.7.2. Product Portfolio
      • 15.2.7.3. Financial Overview
      • 15.2.7.4. SWOT Analysis
      • 15.2.7.5. Strategic Overview
    • 15.2.8. Sera Prognostics
      • 15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.8.2. Product Portfolio
      • 15.2.8.3. Financial Overview
      • 15.2.8.4. SWOT Analysis
      • 15.2.8.5. Strategic Overview
    • 15.2.9. Metabolomic Diagnostics Ltd.
      • 15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.9.2. Product Portfolio
      • 15.2.9.3. Financial Overview
      • 15.2.9.4. SWOT Analysis
      • 15.2.9.5. Strategic Overview
    • 15.2.10. Diabetomics, Inc.
      • 15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.10.2. Product Portfolio
      • 15.2.10.3. Financial Overview
      • 15.2.10.4. SWOT Analysis
      • 15.2.10.5. Strategic Overview
    • 15.2.11. ACON Laboratories, Inc.
      • 15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.11.2. Product Portfolio
      • 15.2.11.3. Financial Overview
      • 15.2.11.4. SWOT Analysis
      • 15.2.11.5. Strategic Overview
    • 15.2.12. DIRUI Industrial Co., Ltd.
      • 15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.2.12.2. Product Portfolio
      • 15.2.12.3. Financial Overview
      • 15.2.12.4. SWOT Analysis
      • 15.2.12.5. Strategic Overview